Marvel LifeSciences withdraws its applications for biosimilar insulin

November 28, 2012 7:22 AM

marvel lifesciences ltd logo Marvel LifeSciences withdraws its applications for biosimilar insulin


Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Solumarv, Isomarv and Combimarv (biosimilar human insulin).

According to the European Medicines Agency’s press release, the Agency has been formally notified by Marvel LifeScience Ltd of its decision to withdraw its applications for centralised marketing authorisations for the medicines Solumarv, Isomarv and Combimarv (human insulin), all 100 IU/ml solution for injection. They were intended to be used for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.

The medicines were developed as ‘biosimilar’ medicines. This means that they are similar to a biological medicine already authorised in the European Union that contains the same active substance (also known as the ‘reference medicine’), Humulin S.

The applications for the marketing authorisation for Solumarv, Isomarv and Combimarv were submitted to the Agency on 5 December 2011. At the time of the withdrawal, all three medicines were under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).

In its official letter, the company stated that, “the decision to withdraw is in order to have sufficient time to repeat and submit bioequivalence T1D [type 1 diabetes] PK/PD [pharmacokinetic/pharmacodynamic] data on each clamp study in order to comply with the planned new insulin guideline …, at a validated CRO [contract research organization].”

More information about Solumarv, Isomarv and Combimarv and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the CHMP meeting of 10-13 December 2012.


Source: EMA press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!